CKD PROGRESSION IN T2D:
AN EVOLVING UNDERSTANDING OF THE DAMAGE BEING DONE
3 MAJOR DRIVERS OF CKD PROGRESSION
IN PATIENTS WITH T2D1-5
Metabolic Drivers
- Elevated HbA1c
Hemodynamic Drivers
- Elevated BP
- High intraglomerular pressure
Inflammatory and Fibrotic Drivers
- Presence and/or release of proinflammatory proteins and profibrotic proteins
CKD Progression
Therapies currently recommended for patients with chronic kidney disease and type 2 diabetes by KDIGO and the EASD mainly focus on metabolic and hemodynamic drivers, leaving inflammation and fibrosis largely unaddressed.6-8
Patients remain at risk of CKD progression even when their HbA1c and BP are controlled.1,2,9,10
Thank you for visiting our site. The questions you'll see throughout are completely voluntary.
NEWS
15/04/2021
Visit us at the virtual WCN 2021
BP: blood pressure; CKD: chronic kidney disease; EASD: European Association for the Study of Diabetes; HbA1c: glycated hemoglobin; KDIGO: Kidney Disease Improving Global Outcomes; T2D: type 2 diabetes.
References:
- Toth-Manikowski S, et al. J Diabetes Res. 2015;2015. doi:10.1155/2015/697010. Return to content
- Alicic RZ, et al. Clin J Am Soc Nephrol. 2017;12(12):2032–2045. Return to content
- Alicic RZ, et al. Adv Chronic Kidney Dis. 2018;25(2):181–191. Return to content
- Black LM, et al. J Histochem Cytochem. 2019;67(9):663–681. Return to content
- Tesch GH, et al. Front Pharmacol. 2017;8. doi:10.3389/fphar.2017.00313. Return to content
- Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. Kidney Int. 2020;98(4S):S1–S115. Return to content
- Cosentino F, et al; ESC Scientific Document Group. Eur Heart J. 2020;41(2):255–323. Return to content
- Tuttle KR, et al. Am J Kidney Dis. 2021;77(1):94–109. Return to content
- Duckworth W, et al; VADT Investigators. N Engl J Med. 2009;360(2):129–139. Return to content
- The ACCORD Study Group. N Engl J Med. 2010;362(17):1575–1585. Return to content
- Afkarian M, et al. J Am Soc Nephrol. 2013;24(2):302–308. Return to content
- Wen CP, et al. Kidney Int. 2017;92(2):388–396. Return to content
- Amod A, et al; DEVOTE Study Group. Diabetes Ther. 2020;11(1):53–70. Return to content
- Thomas MC, et al. Nat Rev Dis Primers. 2015;1. doi:10.1038/nrdp.2015.18. Return to content